NASDAQ:GBT - Global Blood Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$46.65 -0.10 (-0.21 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$46.65
Today's Range$45.75 - $47.15
52-Week Range$24.02 - $68.05
Volume431,352 shs
Average Volume620,467 shs
Market Capitalization$2.42 billion
P/E Ratio-16.90
Dividend YieldN/A
Beta4.4

About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics logoGlobal Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease (SCD). The company is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Debt-to-Equity RatioN/A
Current Ratio23.12
Quick Ratio23.12

Price-To-Earnings

Trailing P/E Ratio-16.90
Forward P/E Ratio-12.85
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$10.38 per share
Price / Book4.49

Profitability

EPS (Most Recent Fiscal Year)($2.76)
Net Income$-117,020,000.00
Net MarginsN/A
Return on Equity-38.74%
Return on Assets-35.69%

Miscellaneous

Employees147
Outstanding Shares51,830,000

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics (NASDAQ:GBT) announced its quarterly earnings data on Monday, May, 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.04. During the same period in the prior year, the company posted ($0.60) earnings per share. View Global Blood Therapeutics' Earnings History.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Global Blood Therapeutics.

What price target have analysts set for GBT?

12 equities research analysts have issued 12 month target prices for Global Blood Therapeutics' stock. Their predictions range from $46.00 to $91.00. On average, they expect Global Blood Therapeutics' stock price to reach $72.4167 in the next year. View Analyst Ratings for Global Blood Therapeutics.

What are Wall Street analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
  • 1. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (5/2/2018)
  • 2. Needham & Company LLC analysts commented, "Here we review our expectations for Part A of the HOPE trial which includes survey findings from 36 sickle cell disease (SCD) experts. We believe there is more than one path forward for voxelotor, but we think upside potential could vary significantly based on Part A findings. If reported Part A outcomes meet expectations as defined below, we think the stock could easily return to the $70 level (+60%) it was trading at in January." (4/26/2018)
  • 3. Cantor Fitzgerald analysts commented, "At ASH, Global Blood announced multi-dose Phase 2a data with voxelotor (GBT440), in adolescent (ages 12-17) patients." (12/11/2017)
  • 4. Cowen Inc analysts commented, "GBT reported Q3 earnings last week and provided a brief summary of their progress." (11/9/2017)

Who are some of Global Blood Therapeutics' key competitors?

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 59)
  • Dr. Charles J. Homcy, Founder, Advisor & Director (Age 70)
  • Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 56)
  • Ms. Tricia Borga Suvari Esq., Chief Legal Officer and Sec. (Age 57)
  • Dr. David R. Phillips Ph.D., Founder and Advisor

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Has Global Blood Therapeutics been receiving favorable news coverage?

Headlines about GBT stock have been trending positive on Saturday, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.28 on Accern's scale. They also gave media stories about the company an impact score of 45.24 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.26%), Franklin Resources Inc. (1.20%), Northern Trust Corp (0.93%), Fernwood Investment Management LLC (0.69%), Nexthera Capital LP (0.61%) and Loomis Sayles & Co. L P (0.57%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Lesley Ann Calhoun, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., BlackRock Inc., JPMorgan Chase & Co., Loomis Sayles & Co. L P, Candriam Luxembourg S.C.A., GW&K Investment Management LLC, Eversept Partners LLC and Iguana Healthcare Management LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Charles J Homcy, Deval L Patrick, Jung Choi, Lesley Ann Calhoun and Peter Radovich. View Insider Buying and Selling for Global Blood Therapeutics.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Frontier Capital Management Co. LLC, Columbus Circle Investors, BNP Paribas Arbitrage SA, Royal Bank of Canada, UBS Group AG, Spark Investment Management LLC and Northern Trust Corp. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $46.65.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $2.42 billion. The company earns $-117,020,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Global Blood Therapeutics employs 147 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]


MarketBeat Community Rating for Global Blood Therapeutics (GBT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Global Blood Therapeutics (NASDAQ:GBT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Global Blood Therapeutics in the last 12 months. Their average twelve-month price target is $72.4167, suggesting that the stock has a possible upside of 55.23%. The high price target for GBT is $91.00 and the low price target for GBT is $46.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.923.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $72.4167$73.5833$67.9286$56.7273
Price Target Upside: 55.23% upside60.84% upside12.56% upside47.54% upside

Global Blood Therapeutics (NASDAQ:GBT) Consensus Price Target History

Price Target History for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ:GBT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2018HC WainwrightSet Price TargetBuy$73.00LowView Rating Details
5/21/2018WedbushReiterated RatingOutperform$70.00HighView Rating Details
5/9/2018Cantor FitzgeraldSet Price TargetBuy$69.00MediumView Rating Details
5/8/2018SunTrust BanksLower Price TargetBuy ➝ Buy$80.00 ➝ $77.00HighView Rating Details
5/8/2018OppenheimerLower Price TargetOutperform ➝ Outperform$79.00 ➝ $74.00HighView Rating Details
4/26/2018Needham & Company LLCReiterated RatingBuy$70.00HighView Rating Details
3/21/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$61.00HighView Rating Details
2/28/2018William BlairReiterated RatingBuyHighView Rating Details
2/13/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$75.00MediumView Rating Details
12/11/2017NomuraBoost Price TargetBuy$91.00HighView Rating Details
11/9/2017CowenReiterated RatingBuy$83.00N/AView Rating Details
10/23/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
3/20/2017Roth CapitalSet Price TargetBuy$47.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy ➝ Buy$50.00N/AView Rating Details
9/30/2016Wells Fargo & CoInitiated CoverageOutperform$75.00 ➝ $23.05N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Global Blood Therapeutics (NASDAQ:GBT) Earnings History and Estimates Chart

Earnings by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ:GBT) Earnings Estimates

2018 EPS Consensus Estimate: ($3.64)
2019 EPS Consensus Estimate: ($4.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.94)($0.89)($0.91)
Q2 20184($0.93)($0.83)($0.88)
Q3 20184($0.97)($0.86)($0.91)
Q4 20184($1.02)($0.88)($0.95)
Q1 20193($1.02)($0.94)($0.98)
Q2 20193($1.05)($0.94)($1.01)
Q3 20193($1.13)($0.87)($1.00)
Q4 20193($1.22)($0.90)($1.04)
Q1 20201($1.28)($1.28)($1.28)

Global Blood Therapeutics (NASDAQ GBT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.87)N/AView Earnings Details
5/7/2018Q1 2018($0.91)($0.87)ViewN/AView Earnings Details
2/27/2018Q4 2017($0.7180)($0.94)ViewN/AView Earnings Details
11/2/2017Q3 2017($0.62)($0.66)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.61)($0.55)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.71)($0.60)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.64)($0.74)ViewN/AView Earnings Details
11/9/2016Q316($0.58)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.63)($0.58)ViewN/AView Earnings Details
5/12/2016Q1($0.48)($0.56)ViewN/AView Earnings Details
3/29/2016Q4($0.6350)($0.53)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.71)($0.90)ViewN/AView Earnings Details
9/24/2015Q2 2015($4.04)($4.84)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Global Blood Therapeutics (NASDAQ:GBT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Global Blood Therapeutics (NASDAQ GBT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 95.43%
Insider Trading History for Global Blood Therapeutics (NASDAQ:GBT)
Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ GBT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Jung ChoiInsiderSell3,000$48.25$144,750.00136,077View SEC Filing  
4/17/2018Jung ChoiInsiderSell3,000$45.50$136,500.00137,677View SEC Filing  
3/16/2018Jung ChoiInsiderSell3,000$54.15$162,450.00139,277View SEC Filing  
3/5/2018Lesley Ann CalhounInsiderSell99$60.35$5,974.65View SEC Filing  
2/16/2018Jung ChoiInsiderSell3,000$62.95$188,850.00140,877View SEC Filing  
2/1/2018Peter RadovichInsiderSell812$57.30$46,527.606,221View SEC Filing  
1/23/2018Peter RadovichInsiderSell30,000$60.00$1,800,000.0033,581View SEC Filing  
1/17/2018Jung ChoiInsiderSell3,000$52.85$158,550.00137,255View SEC Filing  
1/10/2018Peter RadovichInsiderSell15,000$50.00$750,000.0017,684View SEC Filing  
12/19/2017Perceptive Advisors LlcMajor ShareholderBuy175,000$38.00$6,650,000.00View SEC Filing  
12/18/2017Jung ChoiInsiderSell3,000$36.55$109,650.00135,255View SEC Filing  
10/30/2017Peter RadovichVPSell12,500$35.00$437,500.002,684View SEC Filing  
10/27/2017Charles J HomcyDirectorSell70,000$33.97$2,377,900.0083,328View SEC Filing  
10/17/2017Jung ChoiInsiderSell3,000$32.65$97,950.00138,455View SEC Filing  
9/29/2017Jung ChoiInsiderSell3,000$30.00$90,000.00140,055View SEC Filing  
8/31/2017Jung ChoiInsiderSell3,000$30.00$90,000.00141,655View SEC Filing  
7/25/2017Deval L PatrickDirectorSell27,053$29.69$803,203.5712,053View SEC Filing  
7/21/2017Jung ChoiInsiderSell3,000$30.00$90,000.00143,255View SEC Filing  
4/6/2017Robert I TepperMajor ShareholderSell31,225$33.23$1,037,606.75229,773View SEC Filing  
12/16/2016Kevin P StarrMajor ShareholderSell108,955$16.00$1,743,280.0082,544View SEC Filing  
1/7/2016John SchembriinsiderBuy1,500$21.57$32,355.001,500View SEC Filing  
12/22/2015Eleanor RamosinsiderBuy11,000$20.93$230,230.0011,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Global Blood Therapeutics (NASDAQ GBT) News Headlines

Source:
DateHeadline
Global Blood Valuation Gives Goldman Analyst PauseGlobal Blood Valuation Gives Goldman Analyst Pause
www.thestreet.com - May 25 at 5:06 PM
Global Blood Therapeutics: Elucidating The Upcoming Clinical BinaryGlobal Blood Therapeutics: Elucidating The Upcoming Clinical Binary
seekingalpha.com - May 25 at 8:40 AM
Global Blood Therapeutics (GBT) Given a $73.00 Price Target by HC Wainwright AnalystsGlobal Blood Therapeutics (GBT) Given a $73.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 24 at 3:10 PM
FY2018 Earnings Estimate for Global Blood Therapeutics (GBT) Issued By Cantor FitzgeraldFY2018 Earnings Estimate for Global Blood Therapeutics (GBT) Issued By Cantor Fitzgerald
www.americanbankingnews.com - May 24 at 8:36 AM
Global Blood Therapeutics: Potential To Enhance Blood Flow In Patients And Money Flow For InvestorsGlobal Blood Therapeutics: Potential To Enhance Blood Flow In Patients And Money Flow For Investors
seekingalpha.com - May 23 at 8:27 AM
Q2 2018 EPS Estimates for Global Blood Therapeutics Raised by Analyst (GBT)Q2 2018 EPS Estimates for Global Blood Therapeutics Raised by Analyst (GBT)
www.americanbankingnews.com - May 23 at 6:44 AM
Global Blood Therapeutics (GBT) Earns "Outperform" Rating from WedbushGlobal Blood Therapeutics (GBT) Earns "Outperform" Rating from Wedbush
www.americanbankingnews.com - May 22 at 12:55 PM
Global Blood Therapeutics to Post Q1 2019 Earnings of ($0.94) Per Share, Wedbush Forecasts (GBT)Global Blood Therapeutics to Post Q1 2019 Earnings of ($0.94) Per Share, Wedbush Forecasts (GBT)
www.americanbankingnews.com - May 22 at 7:48 AM
Insider Selling: Global Blood Therapeutics (GBT) Insider Sells 3,000 Shares of StockInsider Selling: Global Blood Therapeutics (GBT) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - May 21 at 8:20 PM
Even Momentum Traders Should Study Stock ChartsEven Momentum Traders Should Study Stock Charts
finance.yahoo.com - May 19 at 5:04 PM
GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European ...GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European ...
globenewswire.com - May 19 at 8:59 AM
Global Blood Therapeutics Inc’s (NASDAQ:GBT) Profit OutlookGlobal Blood Therapeutics Inc’s (NASDAQ:GBT) Profit Outlook
finance.yahoo.com - May 19 at 8:59 AM
Global Blood Therapeutics (GBT) Given Average Recommendation of "Buy" by BrokeragesGlobal Blood Therapeutics (GBT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 17 at 5:39 PM
GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) CongressGBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress
finance.yahoo.com - May 17 at 5:00 PM
Lucky Seven: Achaogen Likely To Bounce BackLucky Seven: Achaogen Likely To Bounce Back
seekingalpha.com - May 14 at 4:58 PM
Global Blood Therapeutics (GBT) Expected to Post Earnings of -$0.88 Per ShareGlobal Blood Therapeutics (GBT) Expected to Post Earnings of -$0.88 Per Share
www.americanbankingnews.com - May 14 at 3:19 PM
Sickle Cell Anemia Market Spotlight 2018-2028: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and ...Sickle Cell Anemia Market Spotlight 2018-2028: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and ...
www.businesswire.com - May 11 at 5:22 PM
Global Blood Therapeutics (GBT) PT Set at $73.00 by HC WainwrightGlobal Blood Therapeutics (GBT) PT Set at $73.00 by HC Wainwright
www.americanbankingnews.com - May 10 at 7:05 PM
Global Blood Therapeutics (GBT) PT Set at $69.00 by Cantor FitzgeraldGlobal Blood Therapeutics (GBT) PT Set at $69.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 10 at 7:05 PM
Rounds Report: Global Blood Therapeutics Rallied While Improving FDA Policies To Help NektarRounds Report: Global Blood Therapeutics Rallied While Improving FDA Policies To Help Nektar
seekingalpha.com - May 10 at 9:00 AM
Investors Purchase High Volume of Global Blood Therapeutics Put Options (GBT)Investors Purchase High Volume of Global Blood Therapeutics Put Options (GBT)
www.americanbankingnews.com - May 10 at 7:36 AM
Q2 2018 EPS Estimates for Global Blood Therapeutics Increased by SunTrust Banks (GBT)Q2 2018 EPS Estimates for Global Blood Therapeutics Increased by SunTrust Banks (GBT)
www.americanbankingnews.com - May 10 at 6:54 AM
Oppenheimer Weighs in on Global Blood Therapeutics Q2 2018 Earnings (GBT)Oppenheimer Weighs in on Global Blood Therapeutics' Q2 2018 Earnings (GBT)
www.americanbankingnews.com - May 10 at 6:54 AM
Brokers Issue Forecasts for Global Blood Therapeutics Q2 2018 Earnings (GBT)Brokers Issue Forecasts for Global Blood Therapeutics' Q2 2018 Earnings (GBT)
www.americanbankingnews.com - May 10 at 6:50 AM
Global Blood Therapeutics (GBT) Rating Increased to Strong-Buy at ValuEngineGlobal Blood Therapeutics (GBT) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 8 at 11:26 PM
Markets Confused by Trumps Upcoming Iran DecisionMarkets Confused by Trump's Upcoming Iran Decision
finance.yahoo.com - May 8 at 5:04 PM
Global Blood Therapeutics (GBT) Price Target Lowered to $74.00 at OppenheimerGlobal Blood Therapeutics (GBT) Price Target Lowered to $74.00 at Oppenheimer
www.americanbankingnews.com - May 8 at 3:40 PM
Global Blood Therapeutics (GBT) Issues  Earnings ResultsGlobal Blood Therapeutics (GBT) Issues Earnings Results
www.americanbankingnews.com - May 8 at 11:32 AM
Global Blood Therapeutics (GBT) Price Target Cut to $77.00 by Analysts at SunTrust BanksGlobal Blood Therapeutics (GBT) Price Target Cut to $77.00 by Analysts at SunTrust Banks
www.americanbankingnews.com - May 8 at 10:22 AM
GBT Reports Recent Business Progress and First Quarter 2018 Financial ResultsGBT Reports Recent Business Progress and First Quarter 2018 Financial Results
finance.yahoo.com - May 7 at 5:09 PM
Global Blood: 1Q Earnings SnapshotGlobal Blood: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:09 PM
Global Blood Therapeutics (GBT) Upgraded to Hold at Zacks Investment ResearchGlobal Blood Therapeutics (GBT) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 2 at 12:52 PM
Global Blood Therapeutics: The Anatomy Of A Senseless DropGlobal Blood Therapeutics: The Anatomy Of A Senseless Drop
seekingalpha.com - April 30 at 9:59 AM
[$$] Biotechs Make Headway in Battle Against Sickle Cell Disease[$$] Biotechs Make Headway in Battle Against Sickle Cell Disease
finance.yahoo.com - April 27 at 9:13 AM
Zacks: Brokerages Anticipate Global Blood Therapeutics (GBT) to Announce -$0.92 EPSZacks: Brokerages Anticipate Global Blood Therapeutics (GBT) to Announce -$0.92 EPS
www.americanbankingnews.com - April 27 at 1:26 AM
Needham & Company LLC Reiterates Buy Rating for Global Blood Therapeutics (GBT)Needham & Company LLC Reiterates Buy Rating for Global Blood Therapeutics (GBT)
www.americanbankingnews.com - April 26 at 4:22 PM
Global Blood Therapeutics (GBT) to Release Quarterly Earnings on MondayGlobal Blood Therapeutics (GBT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 23 at 8:26 AM
Global Blood Therapeutics (GBT) Receives Average Rating of "Buy" from AnalystsGlobal Blood Therapeutics (GBT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 22 at 5:34 PM
Global Blood Therapeutics Inc (GBT) Insider Jung Choi Sells 3,000 SharesGlobal Blood Therapeutics Inc (GBT) Insider Jung Choi Sells 3,000 Shares
www.americanbankingnews.com - April 19 at 7:36 PM
Global Blood Therapeutics (GBT) Rating Reiterated by JPMorgan ChaseGlobal Blood Therapeutics (GBT) Rating Reiterated by JPMorgan Chase
www.americanbankingnews.com - April 12 at 7:57 PM
Global Blood Therapeutics (GBT) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowGlobal Blood Therapeutics (GBT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:57 PM
-$0.91 EPS Expected for Global Blood Therapeutics Inc (GBT) This Quarter-$0.91 EPS Expected for Global Blood Therapeutics Inc (GBT) This Quarter
www.americanbankingnews.com - April 10 at 3:10 AM
Zacks Investment Research Upgrades Global Blood Therapeutics (GBT) to BuyZacks Investment Research Upgrades Global Blood Therapeutics (GBT) to Buy
www.americanbankingnews.com - April 7 at 3:52 PM
Global Blood Therapeutics (GBT) Cut to Sell at BidaskClubGlobal Blood Therapeutics (GBT) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 5 at 10:33 AM
Oppenheimer Reiterates "$53.00" Price Target for Global Blood Therapeutics (GBT)Oppenheimer Reiterates "$53.00" Price Target for Global Blood Therapeutics (GBT)
www.americanbankingnews.com - April 4 at 2:58 PM
GBT Announces Participation at the H.C. Wainwright Global Life Sciences ConferenceGBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 3 at 4:56 PM
Global Blood Therapeutics (GBT) Rating Increased to Buy at ValuEngineGlobal Blood Therapeutics (GBT) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 3:36 PM
Global Blood Therapeutics (GBT) Upgraded to "Buy" by BidaskClubGlobal Blood Therapeutics (GBT) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - April 2 at 6:26 PM
Global Blood Therapeutics (GBT) Cut to "Sell" at Zacks Investment ResearchGlobal Blood Therapeutics (GBT) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 2:38 PM
Global Blood Therapeutics Inc (GBT) Receives Consensus Rating of "Buy" from BrokeragesGlobal Blood Therapeutics Inc (GBT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 28 at 5:40 PM

SEC Filings

Global Blood Therapeutics (NASDAQ:GBT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Global Blood Therapeutics (NASDAQ:GBT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Global Blood Therapeutics (NASDAQ GBT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.